Citric acid as a pH-modifying additive in an extended release pellet formulation containing a weakly basic drug

Drug Development and Industrial Pharmacy

Volumn 35, Issue 10, 2009, Pages 1210-1218

  Ploen, Jan ^a   Andersch, Jens ^a   Heschel, Michael ^a   Leopold, Claudia S ^b  

^a APOGEPHA Arzneimittel GmbH   (Germany)

^b UNIVERSITY OF HAMBURG   (Germany)

Author keywords

Coating; Controlled release; Microenvironmental pH; Pellets; Propiverine

Indexed keywords

CITRIC ACID; EUDRAGIT; MICROCRYSTALLINE CELLULOSE; PROPIVERINE; SODIUM CHLORIDE;

ARTICLE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY;

BENZILATES; CELLULOSE; CHEMISTRY, PHARMACEUTICAL; CITRIC ACID; DELAYED-ACTION PREPARATIONS; EXCIPIENTS; HYDROGEN-ION CONCENTRATION; PARASYMPATHOLYTICS; SALTS; SOLUBILITY; TIME FACTORS;

EID: 70350701835     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040902882256     Document Type: Article

References (18)

1. Jünemann K-P, Hessdorfer E, Unamba-Oparah I, Berse M, Brünjes R, Madersbacher H, et al. (2006). Propiverine hydrochloride immediate and extended release: Comparison of efficacy and tolerability in patients with overactive bladder. Urol Int, 77:334-339
2. Dashevsky A, Kolter K, Bodmeier R. (2004). pH-independent release of a basic drug from pellets coated with the extended release polymer dispersion Kollicoat SR 30 D and the enteric polymer dispersion Kollicoat MAE 30 DP. Eur J Pharm Biopharm, 58:45-49
3. Munday DL. (2003). Film coated pellets containing verapamil hydrochloride: Enhanced dissolution into neutral medium. Drug Dev Ind Pharm, 29:575-583
4. Siepe S. (2005). Strategies to improve oral absorption of weakly basic drug substances by modulating the microenvironmental pH. Doctoral Thesis, University of Genf, Switzerland.
5. Thoma K, Zimmer T. (1990). Retardation of weakly basic drugs with diffusion tablets. Int J Pharm, 58:197-202.
6. Thoma K, Ziegler I. (1998). The pH-independent release of fenoldopam from pellets with insoluble film coats. Eur J Pharm Biopharm, 46:105-113
7. Venkatesh GM. (1998). Development of controlled release SK&F 82526-J buffer bead formulations with tartaric acid as the buffer. Pharm Dev Tech, 3:477-485
8. Gruber P, Brickl R, Bozler G, Stricker H. (1980). Neue Dipyridamol-Retardformen und Verfahren zu ihrer Herstellung. EP Patent 0032562, December 17, 1980.
9. Gruber P, Schmid J, Lechner H, Bauer E. (1982). Bromhexin-Retardform und Verfahren zu ihrer Herstellung. EP Patent 0069259, June 18.
10. Thoma K, Knott F. (1991). Retardierung schwach basischer Arzneistoffe. Pharm Ind, 53:778-785
11. Warren SJ, MacRae RJ, Melia CD. (1999). Investigation into the effect of weak acid modifiers on improving the release of dipyridamole from extruded spheronised pellets. Proc Intern Symp Control Rel Bioact Mater, 26: 6370.
12. Guthmann C, Lipp R, Wagner T, Kranz H. (2007). Development of a multiple unit pellet formulation for a weakly basic drug. Drug Dev Ind Pharm, 33:341-349
13. Gramatté T, Gruber P, Güldner P, Heschel M, Pamperin D, Ploen J, et al. (2003). Oral dosage form for propiverine or its pharmaceutically acceptable salts with an extended release of the active ingredient. W.O. Patent 03/030869, October 8, 2003.
14. Kumpugdee M. (2002). Überziehen von pellets mit wässrigen, magensaftresistenten polymerdispersionen in der Wirbelschichtanlage. Doctoral Thesis, University of Hamburg, Germany.
15. Siewert M. (1997). FIP Guidelines for dissolution testing of solid oral products. Pharm Ind, 59:760-766
16. Hogan J. (2001). Coating of tablets and multiparticulates. In: Aulton ME, ed. Pharmaceutics: The science of dosage form design. New York: Churchill Livingstone, 441-448
17. Ozturk AG, Ozturk SS, Palsson BO, Wheatley TA, Dressman JB. (1990). Mechanism of release from pellets coated with an ethylcellulose-based film. J Control Release, 14:203-213
18. Dressman JB, Palsson BO, Ozturk A, Ozturk S. (1994). Mechanisms of release from coated pellets. In: Ghebre-Sellasie I, ed. Multiparticulate oral drug delivery. New York: Marcel Dekker, 285-306.